TBPH Theravance Biopharma Inc

Price (delayed)

$10.4

Market cap

$653.79M

P/E Ratio

0.88

Dividend/share

N/A

EPS

$11.85

Enterprise value

$406.94M

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives ...

Highlights

Theravance Biopharma's debt has shrunk by 92% YoY

Theravance Biopharma's EPS has increased by 5% QoQ

TBPH's equity is down by 8% since the previous quarter

TBPH's revenue is down by 7% year-on-year

Sector: Healthcare

Industry: Biotechnology

Website: http://www.theravance.com

Peers: COLL CORT CPRX CTLT

Key stats

What are the main financial stats of TBPH

Market

Shares outstanding

62.86M

Market cap

$653.79M

Enterprise value

$406.94M

Valuations

Price to earnings (P/E)

0.88

Price to book (P/B)

1.59

Price to sales (P/S)

14.91

EV/EBIT

0.38

EV/EBITDA

0.38

EV/Sales

7.93

Earnings

Revenue

$51.35M

EBIT

$1.06B

EBITDA

$1.07B

Free cash flow

-$185.7M

Per share

EPS

$11.85

Free cash flow per share

-$2.52

Book value per share

$6.56

Revenue per share

$0.7

TBVPS

$8.25

Balance sheet

Total assets

$607.4M

Total liabilities

$165.6M

Debt

$52.16M

Equity

$441.8M

Working capital

$324.75M

Liquidity

Debt to equity

0.12

Current ratio

12.31

Quick ratio

12.02

Net debt/EBITDA

-0.23

Margins

EBITDA margin

2,074.5%

Gross margin

100%

Net margin

1,698.5%

Operating margin

-179.1%

Efficiency

Return on assets

167.2%

Return on equity

1,577.7%

Return on invested capital

176.8%

Return on capital employed

182.7%

Return on sales

2,059.5%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

TBPH stock price

How has the Theravance Biopharma stock price performed over time

Intraday

-1.79%

1 week

-1.52%

1 month

2.67%

1 year

5.37%

YTD

-7.31%

QTD

-7.31%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time

Revenue

$51.35M

Gross profit

$51.35M

Operating income

-$91.96M

Net income

$872.13M

Gross margin

100%

Net margin

1,698.5%

The operating income has soared by 64% YoY and by 32% QoQ

Theravance Biopharma's operating margin has surged by 62% YoY and by 32% QoQ

TBPH's revenue is down by 7% year-on-year

The gross profit has contracted by 7% YoY

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation

P/E

0.88

P/B

1.59

P/S

14.91

EV/EBIT

0.38

EV/EBITDA

0.38

EV/Sales

7.93

Theravance Biopharma's EPS has increased by 5% QoQ

TBPH's equity is down by 8% since the previous quarter

The P/S is 24% lower than the 5-year quarterly average of 20.1 but 6% higher than the last 4 quarters average of 14.3

TBPH's revenue is down by 7% year-on-year

Efficiency

How efficient is Theravance Biopharma business performance

The ROIC has grown by 23% from the previous quarter

The company's return on assets fell by 9% QoQ

Dividends

What is TBPH's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time

TBPH's current ratio has surged by 189% year-on-year

Theravance Biopharma's total liabilities has shrunk by 77% YoY and by 41% QoQ

Theravance Biopharma's debt is 88% lower than its equity

The debt to equity has soared by 106% YoY and by 9% QoQ

Theravance Biopharma's debt has shrunk by 92% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.